Moderna (MRNA)
(Delayed Data from NSDQ)
$60.20 USD
-0.87 (-1.42%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $60.29 +0.09 (0.15%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$60.20 USD
-0.87 (-1.42%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $60.29 +0.09 (0.15%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Zacks News
AstraZeneca (AZN) to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.
Gilead (GILD) Gears Up to Report Q4 Earnings: Whats in Store?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2023 results.
Moderna (MRNA) Stock Moves -1.39%: What You Should Know
by Zacks Equity Research
Moderna (MRNA) concluded the recent trading session at $101.05, signifying a -1.39% move from its prior day's close.
The Zacks Analyst Blog Highlights Oracle, Progressive, MercadoLibre, Moderna and Agilent
by Zacks Equity Research
Oracle, Progressive, MercadoLibre, Moderna and Agilent are included in this Analyst Blog.
Top Stock Reports for Oracle, Progressive & MercadoLibre
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Oracle Corporation (ORCL), The Progressive Corporation (PGR) and MercadoLibre, Inc. (MELI).
Can Moderna's (MRNA) Launches Reduce COVID Sales Dependency?
by Zacks Equity Research
With COVID-19 vaccine sales declining, Moderna (MRNA) is accelerating the development of its non-COVID pipeline. It is gearing up for potential product launches over the next five years.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Moderna (MRNA) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $101.11, marking a -0.79% move from the previous day.
Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
Moderna (MRNA) closed at $100.35 in the latest trading session, marking a -1.77% move from the prior day.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Biotech Stock Roundup: REGN Down on Eylea Update, MRNA Gains on Preliminary Results
by Zacks Equity Research
Preliminary Q4 and 2023 results from Regeneron (REGN) and Moderna (MRNA) were key highlights this week in the biotech sector.
Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
The latest trading day saw Moderna (MRNA) settling at $109.46, representing a -0.65% change from its previous close.
Moderna (MRNA) Issues 2023 Preliminary Results, Stock Up 4%
by Zacks Equity Research
Moderna (MRNA) reports unaudited product sales of around $6.7 billion for 2023, meeting its previously issued guidance. Share price rises following the announcement.
Moderna (MRNA) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $108.66, moving +0.07% from the previous trading session.
Time to Buy Moderna-Heavy ETFs on Vaccine Optimism?
by Sanghamitra Saha
Shares of Moderna witnessed a significant increase of more than 13% on Jan 2, 2024, driven by Oppenheimer's decision to upgrade the stock to "outperform," as quoted on CNBC.
Why Moderna (MRNA) Stock Price Was Up 13% on Tuesday
by Zacks Equity Research
Moderna (MRNA) surges after analysts at Oppenheimer upgraded its rating in anticipation of the company marketing five products by 2026.
Moderna (MRNA) Moves 13.1% Higher: Will This Strength Last?
by Zacks Equity Research
Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Company News for Jan 3, 2024
by Zacks Equity Research
Companies in The News Are: MRNA, RCL, NVDA, MRK
Why the Market Dipped But Moderna (MRNA) Gained Today
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $99.45, marking a +0.67% move from the previous day.
Stock Market News for Dec 28, 2023
by Zacks Equity Research
Wall Street closed higher on Wednesday, with the S&P 500, the Dow and the Nasdaq notching their longest winning streak since 2017.
Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More
by Zacks Equity Research
Compugen (CGEN) and Moderna (MRNA) are in the news on collaboration and study updates, respectively.
FDA Expands Merck's (MRK) Welireg Label in Renal Cell Carcinoma
by Zacks Equity Research
Per Merck (MRK), the latest FDA approval to Welireg marks the first time a new treatment has been approved in a novel therapeutic class in advanced renal cell carcinoma since 2015.
Moderna (MRNA) Soars on Upbeat Data From Cancer Therapy Study
by Zacks Equity Research
Three-year follow up data from a mid-stage study shows that treatment with Moderna (MRNA)/Merck's cancer combination therapy reduces recurrence/death risk in certain melanoma patients by half.
Pharma Stock Roundup: PFE Issues Weak 2024 View, AZN to Buy Icosavax & More
by Kinjel Shah
Pfizer (PFE) issues a disappointing outlook for 2024. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax.
Pfizer (PFE) Stock Sinks on Weak 2024 View as COVID Sales Fall
by Zacks Equity Research
Pfizer's (PFE) shares decline almost 7% in response to the muted guidance for 2024. Revenues are expected to be in the range of $58.5 to $61.5 billion, while adjusted EPS is expected in the range of $2.05 to $2.25.